You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Versant Venture Capital IV | 2,736,032 | 0 | 2,736,032 | 0 | 2,736,032 | 6.74% |
| Versant Side Fund IV | 16,224 | 0 | 16,224 | 0 | 16,224 | 0.04% |
| Versant Ventures IV | 0 | 2,752,256 | 0 | 2,752,256 | 2,752,256 | 6.78% |
| Versant Venture Capital V | 1,629,204 | 0 | 1,629,204 | 0 | 1,629,204 | 4.01% |
| Versant Affiliates Fund V | 47,801 | 0 | 47,801 | 0 | 47,801 | 0.12% |
| Versant Ophthalmic Affiliates Fund I | 52,987 | 0 | 52,987 | 0 | 52,987 | 0.13% |
| Versant Ventures V | 0 | 1,729,992 | 0 | 1,729,992 | 1,729,992 | 4.26% |
| Versant Venture Capital V (Canada) | 123,994 | 0 | 123,994 | 0 | 123,994 | 0.31% |
| Versant Ventures V GP-GP (Canada), Inc | 0 | 123,994 | 0 | 123,994 | 123,994 | 0.31% |
| Versant Ventures V (Canada) | 0 | 123,994 | 0 | 123,994 | 123,994 | 0.31% |
Page 1 of 18 – SEC Filing
|
| UNITED STATES |
|
|
| SECURITIES AND EXCHANGE COMMISSION |
|
|
| Washington, D.C. 20549 |
|
|
|
|
|
|
| SCHEDULE 13D |
|
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT
TO RULE 13d-2(a)
(Amendment No. 1)*
CRISPR THERAPEUTICS AG
(Name of Issuer)
Common Stock, par value CHF 0.03 per share
(Title of Class of Securities)
H17182108
(CUSIP Number)
Versant Ventures IV, LLC
Robin L. Praeger
One Sansome Street, Suite 3630
San Francisco, CA 94104
415-801-8100
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
September 5, 2017
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks
If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.
Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
13D Filing: Lone Star Value Management and Crossroads Systems Inc (CRDS)
13D Filing: Glenview Capital and Tenet Healthcare Corp (THC)
13D Filing: Huber Capital Management and Teekay Tankers Ltd (TNK)
13D Filing: GAMCO Investors and Gabelli Global Small & Mid Cap Value Trust...
13D Filing: Corvex Capital and Energen Corporation (EGN)
13D Filing: Silver Lake Partners and Vmware Inc. (VMW)
